-

$undefined

N/A

(N/A)

Calithera Biosciences OTC Markets EXMKT:CALA Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Location: 343 Oyster Point Boulevard, South San Francisco, CA, 94080, United States | Website: https://www.calithera.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-1.443M

Cash

25.45M

Avg Qtr Burn

-10.9M

Short % of Float

8.64%

Insider Ownership

0.00%

Institutional Own.

0.00%

Qtr Updated

12/31/22

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CB-1158 (INCB00158) (Arginase Inhibitor) Details Solid tumor/s	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Pancreatic cancer, Non-small cell lung carcinoma, Colorectal cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Renal cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Renal cell carcinoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-659 (mivavotinib) Details Non-Hodgkin lymphoma, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CB-839 (Glutaminase Inhibitor Telaglenastat) Details Non-small cell lung carcinoma, Solid tumor/s	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.